Overview Dividends

(VIR) Vir Biotechnology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92764N1028

Hepatitis, Influenza, Coronavirus, RSV, T-cell, Therapies

VIR EPS (Earnings per Share)

EPS (Earnings per Share) of VIR over the last years for every Quarter: "2020-03": -0.71262567131571, "2020-06": -0.27106288272728, "2020-09": -0.67250929768406, "2020-12": -0.82994947983318, "2021-03": -1.3222762023006, "2021-06": 0.46201509828836, "2021-09": 0.8249859548883, "2021-12": 3.9233340429267, "2022-03": 3.8548921550992, "2022-06": -0.57752359380898, "2022-09": 1.2989605322336, "2022-12": -0.76304307010627, "2023-03": -1.0554327576809, "2023-06": -1.4529039804086, "2023-09": -1.2168701075884, "2023-12": -0.86155585667505, "2024-03": -0.48252299294947, "2024-06": -1.015739864659, "2024-09": -1.5639278762422, "2024-12": -0.76448917834353, "2025-03": -0.87994384188435, "2025-06": -0.80144748531929,
EPS Growth (3Y CAGR): 0.00%
EPS Trend (3Y Correlation): -39.7%

VIR Revenue

Revenue of VIR over the last years for every Quarter: 2020-03: 0.487, 2020-06: 66.269, 2020-09: 0.188, 2020-12: 0.301, 2021-03: 0.605, 2021-06: 173.986, 2021-09: 102.713, 2021-12: 809.756, 2022-03: 1229.938, 2022-06: -42.687, 2022-09: 371.432, 2022-12: 21.789, 2023-03: 46.712, 2023-06: -12.722, 2023-09: -4.098, 2023-12: 16.787, 2024-03: 56.376, 2024-06: 3.075, 2024-09: 2.38, 2024-12: 11.278, 2025-03: 1.794, 2025-06: 1.214,
Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -25.1%

Description: VIR Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutic solutions for serious infectious diseases. With a robust pipeline of investigational therapies targeting various viral infections, including hepatitis delta virus (HDV), influenza A and B, coronavirus disease 2019, and human papillomavirus (HPV), the company is well-positioned to address significant unmet medical needs. Its strategic partnerships with prominent organizations, such as the Gates Foundation, Alnylam Pharmaceuticals, and GlaxoSmithKline, underscore its commitment to advancing its research and development efforts.

The companys diverse portfolio of preclinical and clinical-stage candidates is a testament to its dedication to tackling complex infectious diseases. Notably, its masked T-cell engagers (TCEs) technology, licensed from Sanofi, has the potential to revolutionize the treatment of various cancers and infectious diseases. With a strong foundation in San Francisco, California, Vir Biotechnology is poised to make a meaningful impact in the biopharmaceutical industry.

Analyzing the , we observe that the stock has been trading near its 20-day simple moving average (SMA20) of $5.11, with a recent price of $5.23. The stock is currently below its 50-day SMA of $5.33 and significantly below its 200-day SMA of $7.47, indicating a potential downtrend. However, the average true range (ATR) of 0.30 (5.79%) suggests moderate volatility, which could be exploited by traders. Considering the , the companys market capitalization stands at $725.75 million, with a forward price-to-earnings ratio of 4.36, indicating a relatively low valuation.

Forecasting the stocks performance, we can expect a potential rebound if the company announces positive clinical trial results or secures additional strategic partnerships. Based on the and , a possible price target could be around $7.00, representing a 34% increase from the current price. However, this would require a significant improvement in the companys clinical pipeline and/or a more favorable market environment. Conversely, failure to meet clinical trial expectations or a decline in investor sentiment could lead to a further decline in the stock price, potentially testing the 52-week low of $4.50.

VIR Stock Overview

Market Cap in USD 713m
Sub-Industry Biotechnology
IPO / Inception 2019-10-11

VIR Stock Ratings

Growth Rating -83.9%
Fundamental 28.7%
Dividend Rating -
Return 12m vs S&P 500 -48.8%
Analyst Rating 4.0 of 5

VIR Dividends

Currently no dividends paid

VIR Growth Ratios

Growth Correlation 3m -44.2%
Growth Correlation 12m -78.1%
Growth Correlation 5y -92.6%
CAGR 5y -37.98%
CAGR/Max DD 3y -0.44
CAGR/Mean DD 3y -0.55
Sharpe Ratio 12m -0.50
Alpha -45.14
Beta 0.128
Volatility 56.58%
Current Volume 1360.1k
Average Volume 20d 1113.2k
Stop Loss 4.4 (-8.1%)
Signal -1.09

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-550.2m TTM) > 0 and > 6% of Revenue (6% = 1000.0k TTM)
FCFTA -0.38 (>2.0%) and ΔFCFTA 9.90pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 3784 % (prev 1538 %; Δ 2247 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.38 (>3.0%) and CFO -457.4m > Net Income -550.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (138.4m) change vs 12m ago 1.62% (target <= -2.0% for YES)
Gross Margin 95.53% (prev 80.31%; Δ 15.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.16% (prev 4.32%; Δ -3.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -5.73

(A) 0.53 = (Total Current Assets 735.7m - Total Current Liabilities 105.0m) / Total Assets 1.19b
(B) -0.83 = Retained Earnings (Balance) -991.7m / Total Assets 1.19b
(C) -0.33 = EBIT TTM -475.1m / Avg Total Assets 1.43b
(D) -4.06 = Book Value of Equity -993.9m / Total Liabilities 245.1m
Total Rating: -5.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.72

1. Piotroski 1.0pt = -4.0
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.26 = 2.47
5. Debt/Ebitda -0.53 = -2.50
6. ROIC - WACC -48.21% = -12.50
7. RoE -50.22% = -2.50
8. Rev. Trend -25.05% = -1.25
9. Rev. CAGR 0.0% = 0.0
10. EPS Trend -39.73% = -0.99
11. EPS CAGR 0.0% = 0.0

What is the price of VIR shares?

As of September 16, 2025, the stock is trading at USD 4.79 with a total of 1,360,122 shares traded.
Over the past week, the price has changed by -7.71%, over one month by +5.97%, over three months by -8.59% and over the past year by -39.14%.

Is Vir Biotechnology a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Vir Biotechnology (NASDAQ:VIR) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 28.72 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIR is around 3.08 USD . This means that VIR is currently overvalued and has a potential downside of -35.7%.

Is VIR a buy, sell or hold?

Vir Biotechnology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VIR.
  • Strong Buy: 2
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the VIR price?

Issuer Target Up/Down from current
Wallstreet Target Price 17.2 259.5%
Analysts Target Price 17.2 259.5%
ValueRay Target Price 3.3 -30.7%

Last update: 2025-09-12 04:47

VIR Fundamental Data Overview

Market Cap USD = 712.6m (712.6m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 687.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 4.3611
P/S = 37.5073
P/B = 0.7522
Beta = 1.28
Revenue TTM = 16.7m USD
EBIT TTM = -475.1m USD
EBITDA TTM = -466.4m USD
Long Term Debt = 140.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 105.0m USD (from totalCurrentLiabilities, last quarter)
Debt = 245.1m USD (Calculated: Short Term 105.0m + Long Term 140.1m)
Net Debt = -205.9m USD (from netDebt column, last quarter)
Enterprise Value = 270.7m USD (712.6m + Debt 245.1m - CCE 687.0m)
Interest Coverage Ratio = unknown (Ebit TTM -475.1m / Interest Expense TTM 0.0)
FCF Yield = -167.6% (FCF TTM -453.7m / Enterprise Value 270.7m)
FCF Margin = -2722 % (FCF TTM -453.7m / Revenue TTM 16.7m)
Net Margin = -3302 % (Net Income TTM -550.2m / Revenue TTM 16.7m)
Gross Margin = 95.53% ((Revenue TTM 16.7m - Cost of Revenue TTM 745.0k) / Revenue TTM)
Tobins Q-Ratio = -0.27 (set to none) (Enterprise Value 270.7m / Book Value Of Equity -993.9m)
Interest Expense / Debt = 0.10% (Interest Expense 239.0k / Debt 245.1m)
Taxrate = 21.0% (US default)
NOPAT = -475.1m (EBIT -475.1m, no tax applied on loss)
Current Ratio = 7.01 (Total Current Assets 735.7m / Total Current Liabilities 105.0m)
Debt / Equity = 0.26 (Debt 245.1m / last Quarter total Stockholder Equity 947.5m)
Debt / EBITDA = -0.53 (Net Debt -205.9m / EBITDA -466.4m)
Debt / FCF = -0.54 (Debt 245.1m / FCF TTM -453.7m)
Total Stockholder Equity = 1.10b (last 4 quarters mean)
RoA = -46.14% (Net Income -550.2m, Total Assets 1.19b )
RoE = -50.22% (Net Income TTM -550.2m / Total Stockholder Equity 1.10b)
RoCE = -38.45% (Ebit -475.1m / (Equity 1.10b + L.T.Debt 140.1m))
RoIC = -43.36% (NOPAT -475.1m / Invested Capital 1.10b)
WACC = 4.85% (E(712.6m)/V(957.7m) * Re(6.49%)) + (D(245.1m)/V(957.7m) * Rd(0.10%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 84.85 | Cagr: 0.23%
Discount Rate = 6.49% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -453.7m)
Revenue Correlation: -25.05 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -9.05
EPS Correlation: -39.73 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 51.71

Additional Sources for VIR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle